Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02870478 · ClinicalTrials.gov registry record · Phase 3

The Effects of Low Concentration Atropine on Pupil Size and Accommodation

A Phase 3 study, sponsored by University of California, Berkeley.

Completed
Registry status
Phase 3
Development phase
32
Enrollment target

NCT02870478 is a Phase 3 study that has completed, run by University of California, Berkeley. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02870478, a Phase 3 study, has completed, sponsored by University of California, Berkeley.

COMPLETED
Registry status
Phase 3
Development phase
32 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether less frequent dosing of atropine drops may be as effective as daily dosing for the treatment of progressive myopia.

Interventions

  • DRUG Atropine

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2016-07
Est. Completion 2019-11-20
Phase Phase 3

Sponsor

University of California, Berkeley

72 total trials

What the Registry Record Tells You About NCT02870478

The ClinicalTrials.gov registry entry for NCT02870478 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Berkeley, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Atropine is the first listed.

NCT02870478 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02870478 about?

NCT02870478 is a clinical study titled "The Effects of Low Concentration Atropine on Pupil Size and Accommodation". The purpose of this study is to determine whether less frequent dosing of atropine drops may be as effective as daily dosing for the treatment of progressive myopia.

What is the current status of trial NCT02870478?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2016-07. Estimated completion is 2019-11-20.

What interventions are being tested in trial NCT02870478?

The interventions under investigation include: Atropine (DRUG).

Who is sponsoring clinical trial NCT02870478?

This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.